PhiBio Therapeutics

PhiBio Therapeutics is a pre-clinical stage biotechnology company focused on developing a novel class of biologics called Phi-bodies. These are engineered cell-penetrating antibodies designed to reach and inhibit high-value intracellular targets that are traditionally considered undruggable by standard monoclonal antibodies. The company's proprietary platform enables the delivery of potent therapeutic proteins directly into the cytosol of cancer cells by overcoming the endosomal barrier. PhiBio's initial pipeline targets major oncogenic drivers such as KRAS and MYC, which are prevalent in pancreatic, lung, and colorectal cancers. By combining the high specificity of antibodies with the ability to cross cell membranes, PhiBio aims to transform the treatment landscape for various hard-to-treat malignancies.